Background: Gait speed is an important measure of lower extremity physical performance in older adults and is predictive of disability and mortality. The biological pathways involved in the decline of lower extremity physical performance are not well understood. We used a targeted metabolomics approach to identify plasma metabolites predictive of change in gait speed over time. Methods: Gait speed was measured at baseline and over median follow-up of 50.5 months in 504 adults, aged ≥50 years, who had two or more study visits in the Baltimore Longitudinal Study of Aging (BLSA). Plasma metabolites were measured using targeted mass spectrometry (AbsoluteIDQ p180 Kit, Biocrates). Results: Of 148 plasma metabolites (amino acids, biogenic amines, hexoses, glycerophospholipids) measured, eight were significantly associated with gait speed at baseline, independent of age and sex: hexoses (r = -0.148, p < .001), [sphingomyelin (SM) 16:1 (r = -0.091, p = .0009), SM 18:0 (r = -0.085, p = .002), SM 18:1 (r = -0.128, p < .0001], phosphatidylcholine aa 32:3 (r = -0.088, p = .001), lysophosphatidylcholine (LPC) 17:0 (r = 0.083, p = .003), LPC 18:1 (r = 0.089, p = .001), and LPC 18:2 (r = 0.104, p < .0001). Adjusting for baseline age, sex, and chronic diseases, baseline plasma LPC 18:2 was an independent predictor of the rate of change of gait speed over subsequent follow-up (p = .003). No other plasma metabolites were significantly associated longitudinal changes of gait speed over time. Conclusions: Low plasma LPC 18:2, which has previously been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment, is an independent predictor of decline in gait speed in older adults.
Background: Gait speed is an important measure of lower extremity physical performance in older adults and is predictive of disability and mortality. The biological pathways involved in the decline of lower extremity physical performance are not well understood. We used a targeted metabolomics approach to identify plasma metabolites predictive of change in gait speed over time. Methods: Gait speed was measured at baseline and over median follow-up of 50.5 months in 504 adults, aged ≥50 years, who had two or more study visits in the Baltimore Longitudinal Study of Aging (BLSA). Plasma metabolites were measured using targeted mass spectrometry (AbsoluteIDQ p180 Kit, Biocrates). Results: Of 148 plasma metabolites (amino acids, biogenic amines, hexoses, glycerophospholipids) measured, eight were significantly associated with gait speed at baseline, independent of age and sex: hexoses (r = -0.148, p < .001), [sphingomyelin (SM) 16:1 (r = -0.091, p = .0009), SM 18:0 (r = -0.085, p = .002), SM 18:1 (r = -0.128, p < .0001], phosphatidylcholine aa 32:3 (r = -0.088, p = .001), lysophosphatidylcholine (LPC) 17:0 (r = 0.083, p = .003), LPC 18:1 (r = 0.089, p = .001), and LPC 18:2 (r = 0.104, p < .0001). Adjusting for baseline age, sex, and chronic diseases, baseline plasma LPC 18:2 was an independent predictor of the rate of change of gait speed over subsequent follow-up (p = .003). No other plasma metabolites were significantly associated longitudinal changes of gait speed over time. Conclusions: Low plasma LPC 18:2, which has previously been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment, is an independent predictor of decline in gait speed in older adults.
Authors: Morag E Taylor; Danielle A Lasschuit; Stephen R Lord; Kim Delbaere; Susan E Kurrle; A Stefanie Mikolaizak; Tasha Kvelde; Jacqueline C T Close Journal: Arch Gerontol Geriatr Date: 2017-07-31 Impact factor: 3.250
Authors: Michael S Lustgarten; Lori Lyn Price; Angela Chale; Edward M Phillips; Roger A Fielding Journal: J Gerontol A Biol Sci Med Sci Date: 2013-10-01 Impact factor: 6.053
Authors: Shailaja P Rao; Monika Riederer; Margarete Lechleitner; Martin Hermansson; Gernot Desoye; Seth Hallström; Wolfgang F Graier; Saša Frank Journal: PLoS One Date: 2013-05-31 Impact factor: 3.240
Authors: Andrea Ganna; Samira Salihovic; Johan Sundström; Corey D Broeckling; Asa K Hedman; Patrik K E Magnusson; Nancy L Pedersen; Anders Larsson; Agneta Siegbahn; Mihkel Zilmer; Jessica Prenni; Johan Arnlöv; Lars Lind; Tove Fall; Erik Ingelsson Journal: PLoS Genet Date: 2014-12-11 Impact factor: 5.917
Authors: Melissa N Barber; Steve Risis; Christine Yang; Peter J Meikle; Margaret Staples; Mark A Febbraio; Clinton R Bruce Journal: PLoS One Date: 2012-07-25 Impact factor: 3.240
Authors: Lina Ma; Lolita S Nidadavolu; Huanle Yang; Jackie Langdon; Reyhan Westbrook; Benjamin M W Tsui; Taek-Soo Lee; Jared Hinson; Shizhang Ling; Ruth Marx-Rattner; Yuqiong Wu; Tu Nguyen; Jessica Tan; Mohammed Khadeer; Ruin Moaddel; Anne Le; Jeremy D Walston; Peter M Abadir Journal: J Gerontol A Biol Sci Med Sci Date: 2021-01-18 Impact factor: 6.053
Authors: Maximilian Unfried; Li Fang Ng; Amaury Cazenave-Gassiot; Krishna Chaithanya Batchu; Brian K Kennedy; Markus R Wenk; Nicholas Tolwinski; Jan Gruber Journal: Front Aging Date: 2022-05-27
Authors: Megan M Marron; Stacy G Wendell; Robert M Boudreau; Clary B Clish; Adam J Santanasto; George C Tseng; Joseph M Zmuda; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2020-11-13 Impact factor: 6.053
Authors: Jovia L Nierenberg; Jiang He; Changwei Li; Xiaoying Gu; Mengyao Shi; Alexander C Razavi; Xuenan Mi; Shengxu Li; Lydia A Bazzano; Amanda H Anderson; Hua He; Wei Chen; Jack M Guralnik; Jason M Kinchen; Tanika N Kelly Journal: Aging (Albany NY) Date: 2020-06-01 Impact factor: 5.682